From inflammation to precision medicine in colon cancer: Methodological considerations and future directions

A recent study by Zhu SS <i>et al</i> evaluated the prognostic value of the systemic immune-inflammation index and serum lactoferrin in older patients with colon cancer. While this work highlights the potential role of inflammation-based biomarkers in predicting survival, several methodological and analytical concerns limitations constrain its clinical applicability. These include a small sample size, a single-center observational design, a short follow-up duration, incomplete adjustment for confounding variables, and reliance on cut-off thresholds derived from receiver operating characteristic analyses, which increases the risk of overfitting. Moreover, the reported predictive accuracy was moderate, yet the findings were presented as clinically decisive, warranting caution in interpretation. Future studies should aim for multicenter, prospective cohorts with larger sample sizes, longer follow-up periods, and the integration of established prognostic indices and molecular biomarkers. Incorporating rigorous statistical validation and exploring biomarker dynamics over time would strengthen external validity. Addressing these issues could advance the development of reliable, inflammation-based prognostic tools and support individualized treatment strategies for elderly colon cancer patients.